

Probiomics Limited

ABN 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422

F: +61 2 9844 5445

W: www.probiomics.com.au

**The Australian Stock Exchange Limited
Companies Announcements Office
SYDNEY**

12 May 2009

PCC SHOWN TO BE EFFECTIVE IN BOOSTING FLU VACCINE IN CLINICAL TRIAL

Probiomics wishes to advise that the outcome of double blind, placebo controlled clinical trial examining the ability of PCC[®], its proprietary probiotic strain, to boost the immune response to influenza vaccine during an influenza period, has been accepted for publication in the International Journal of Probiotics and Prebiotics.

The paper reports that PCC[®] was able to significantly boost the immune response to the flu vaccine as measured by the H1N1 titre, and to significantly reduce the number of subjects who did not respond to vaccination. Additionally, those taking PCC[®] had significantly fewer days of respiratory symptoms (average of 2 days) compared to those on placebo (who experienced on average 5 days of illness).

Importantly, there were no adverse events experienced in the study.

The study concludes that oral consumption of PCC[®] (*Lactobacillus fermentum* VRI003) has the potential to provide a low cost and low risk adjuvant* for influenza vaccine. As such, Probiomics believes that PCC may have an important role to play in any future influenza pandemic.

The full paper, titled "Use Of Probiotic Bacteria As An Adjuvant for Influenza Vaccine" can be viewed at www.probiomics.com.au under the latest news.

* An adjuvant is an agent that boosts or enhances the immune response of the vaccine.

Probiomics Limited

ABN 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422

F: +61 2 9844 5445

W: www.probiomics.com.au

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary

Tel: 02 9844 5422

Email ashok.jairath@probiomics.com.au

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC[®]

PCC[®] has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics' commercial objective is to earn royalties from licensing PCC[®] to distribution companies selling products in global markets.